very funny time to have my pharmacoeconomics final
December 8, 2024 at 7:11 PM
very funny time to have my pharmacoeconomics final
*solemnly raising my hand during the pharmacoeconomics poster presentation on Exblifep vs Zosyn for ESBLs* “In your sensitivity analysis did you consider the negative effects of forcing people to say ‘Exblifep’ out loud in serious conversation?”
November 25, 2024 at 5:51 PM
*solemnly raising my hand during the pharmacoeconomics poster presentation on Exblifep vs Zosyn for ESBLs* “In your sensitivity analysis did you consider the negative effects of forcing people to say ‘Exblifep’ out loud in serious conversation?”
Thrilled to have successfully defended my PhD on the Pharmacoepidemiology & Pharmacoeconomics of Drug-Drug Interactions in the Older Community-Dwelling Population.
Thank you to my examiners, Dr Shane Cullinan & Prof Elisabetta Poluzzi, for an enjoyable discussion this afternoon.
Thank you to my examiners, Dr Shane Cullinan & Prof Elisabetta Poluzzi, for an enjoyable discussion this afternoon.
December 16, 2024 at 5:30 PM
Thrilled to have successfully defended my PhD on the Pharmacoepidemiology & Pharmacoeconomics of Drug-Drug Interactions in the Older Community-Dwelling Population.
Thank you to my examiners, Dr Shane Cullinan & Prof Elisabetta Poluzzi, for an enjoyable discussion this afternoon.
Thank you to my examiners, Dr Shane Cullinan & Prof Elisabetta Poluzzi, for an enjoyable discussion this afternoon.
📢 Call for papers: Special Issue on The Health Economics of Artificial Intelligence in Medicine
📒 Journal: Pharmacoeconomics and Policy
📅 Submission deadline: 30 June 2027
🔗 Check more: https://ow.ly/jQrc50ZRZg2
#HealthEconomics #ArtificialIntelligence #Medicine
📒 Journal: Pharmacoeconomics and Policy
📅 Submission deadline: 30 June 2027
🔗 Check more: https://ow.ly/jQrc50ZRZg2
#HealthEconomics #ArtificialIntelligence #Medicine
September 29, 2026 at 6:00 AM
📢 Call for papers: Special Issue on The Health Economics of Artificial Intelligence in Medicine
📒 Journal: Pharmacoeconomics and Policy
📅 Submission deadline: 30 June 2027
🔗 Check more: https://ow.ly/jQrc50ZRZg2
#HealthEconomics #ArtificialIntelligence #Medicine
📒 Journal: Pharmacoeconomics and Policy
📅 Submission deadline: 30 June 2027
🔗 Check more: https://ow.ly/jQrc50ZRZg2
#HealthEconomics #ArtificialIntelligence #Medicine
We have a record number of postdoc positions open at @econmuni.bsky.social!
Learn more: www.muni.cz/en/about-us/...
- Health Economics
- Empirical Economics/Labor Economics
- Health Economic Microsimulation & Pharmacoeconomics
- Political Economics and/or Behavioral Economics
Learn more: www.muni.cz/en/about-us/...
- Health Economics
- Empirical Economics/Labor Economics
- Health Economic Microsimulation & Pharmacoeconomics
- Political Economics and/or Behavioral Economics
December 20, 2024 at 2:24 PM
We have a record number of postdoc positions open at @econmuni.bsky.social!
Learn more: www.muni.cz/en/about-us/...
- Health Economics
- Empirical Economics/Labor Economics
- Health Economic Microsimulation & Pharmacoeconomics
- Political Economics and/or Behavioral Economics
Learn more: www.muni.cz/en/about-us/...
- Health Economics
- Empirical Economics/Labor Economics
- Health Economic Microsimulation & Pharmacoeconomics
- Political Economics and/or Behavioral Economics
An assessment of a drug for a rare muscular condition was removed from the website of the National Centre for Pharmacoeconomics, at the request of the Department of Health
NCPE told to remove rare drug assessment from website
An assessment of a drug for a rare muscular condition was removed from the website of the National Centre for Pharmacoeconomics, at the request of the Department of Health.
www.rte.ie
March 4, 2026 at 9:05 AM
An assessment of a drug for a rare muscular condition was removed from the website of the National Centre for Pharmacoeconomics, at the request of the Department of Health
The #Pharmacoeconomics of #Vaccines: Advancing Cost-Effectiveness and Access in Global #Immunization Strategies
link.springer.com/collections/...
Collection on pharmacoeconomics of vaccines, focusing on their economic value, pricing strategies, & policy implications within healthcare systems.
link.springer.com/collections/...
Collection on pharmacoeconomics of vaccines, focusing on their economic value, pricing strategies, & policy implications within healthcare systems.
The Pharmacoeconomics of Vaccines: Advancing Cost-Effectiveness and Access in Global Immunization Strategies
This collection aims to explore the latest advancements in the pharmacoeconomics of vaccines, focusing on their economic value, pricing strategies, and policy ...
link.springer.com
November 28, 2025 at 3:49 PM
The #Pharmacoeconomics of #Vaccines: Advancing Cost-Effectiveness and Access in Global #Immunization Strategies
link.springer.com/collections/...
Collection on pharmacoeconomics of vaccines, focusing on their economic value, pricing strategies, & policy implications within healthcare systems.
link.springer.com/collections/...
Collection on pharmacoeconomics of vaccines, focusing on their economic value, pricing strategies, & policy implications within healthcare systems.
ISPOR Europe 2026 - International Society for Pharmacoeconomics and Outcomes Research
#event #Austria #JEL_I
www.econbiz.de/event/24518
#event #Austria #JEL_I
www.econbiz.de/event/24518
ISPOR Europe 2026 - International Society for Pharmacoeconomics and Outcomes Research
www.econbiz.de
June 3, 2026 at 9:26 AM
ISPOR Europe 2026 - International Society for Pharmacoeconomics and Outcomes Research
#event #Austria #JEL_I
www.econbiz.de/event/24518
#event #Austria #JEL_I
www.econbiz.de/event/24518
🧠 Alzheimer’s disease (AD) care is entering a new era.
In our latest issue, a new Lancet Series highlights crucial next steps in diagnosis, treatment, & prevention of AD globally.
Read this & more: tinyurl.com/259664bs
In our latest issue, a new Lancet Series highlights crucial next steps in diagnosis, treatment, & prevention of AD globally.
Read this & more: tinyurl.com/259664bs
![Cover of The Lancet's Sept 27, 2025 issue. Quote on cover reads: "[...]a substantial body of biological, clinical, public health, and pharmacoeconomics data now allows communities to address the Alzheimer's conundrum [...]. The honest and lively debate among experts will continue."](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ypu6bwefbbzhcvojdj7mz657/bafkreihoztox3qccjdxnc7kqvqdimjiiizggpl5mi426h52egstngeie7m)
September 26, 2025 at 10:32 AM
🧠 Alzheimer’s disease (AD) care is entering a new era.
In our latest issue, a new Lancet Series highlights crucial next steps in diagnosis, treatment, & prevention of AD globally.
Read this & more: tinyurl.com/259664bs
In our latest issue, a new Lancet Series highlights crucial next steps in diagnosis, treatment, & prevention of AD globally.
Read this & more: tinyurl.com/259664bs
We have one more postdoc position open for applications! 👇
Post-doctoral Researcher in Health Economic Microsimulation and/or Pharmacoeconomics
🚨We are reviewing applications on a rolling basis.
www.muni.cz/en/about-us/...
Post-doctoral Researcher in Health Economic Microsimulation and/or Pharmacoeconomics
🚨We are reviewing applications on a rolling basis.
www.muni.cz/en/about-us/...
Post-doctoral Researcher in Health Economic Microsimulation and/or Pharmacoeconomics | Masaryk University
www.muni.cz
February 10, 2025 at 8:35 AM
We have one more postdoc position open for applications! 👇
Post-doctoral Researcher in Health Economic Microsimulation and/or Pharmacoeconomics
🚨We are reviewing applications on a rolling basis.
www.muni.cz/en/about-us/...
Post-doctoral Researcher in Health Economic Microsimulation and/or Pharmacoeconomics
🚨We are reviewing applications on a rolling basis.
www.muni.cz/en/about-us/...
They're amortizing investment in R&D (past & future) into the cost of the treatment, building in the cost of liability risk & accounting for the presently very expensive processing.
But that's not actually how the price is set.
It's set by the alternative cost of care.
But that's not actually how the price is set.
It's set by the alternative cost of care.
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States - PharmacoEconomics
Background and Objective Gene therapies for sickle cell disease (SCD) may offer meaningful benefits for patients and society. This study evaluated the cost-effectiveness of lovotibeglogene autotemcel ...
link.springer.com
March 15, 2025 at 2:25 PM
They're amortizing investment in R&D (past & future) into the cost of the treatment, building in the cost of liability risk & accounting for the presently very expensive processing.
But that's not actually how the price is set.
It's set by the alternative cost of care.
But that's not actually how the price is set.
It's set by the alternative cost of care.
🎉 Congrats to my PhD student Xiaoyu Zhang on her new PharmacoEconomics paper, co-supervised with @samjnorton.bsky.social and other co-authors!
It reviews the economic burden of inflammatory arthritis.
Full text: 🔗 rdcu.be/eIv8o
cc: @khe-kings.bsky.social
It reviews the economic burden of inflammatory arthritis.
Full text: 🔗 rdcu.be/eIv8o
cc: @khe-kings.bsky.social
September 30, 2025 at 2:40 PM
🎉 Congrats to my PhD student Xiaoyu Zhang on her new PharmacoEconomics paper, co-supervised with @samjnorton.bsky.social and other co-authors!
It reviews the economic burden of inflammatory arthritis.
Full text: 🔗 rdcu.be/eIv8o
cc: @khe-kings.bsky.social
It reviews the economic burden of inflammatory arthritis.
Full text: 🔗 rdcu.be/eIv8o
cc: @khe-kings.bsky.social
To learn more about SMART, read the paper published on PharmacoEconomics Journal:
'Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART tool' ➡️ link.springer.com/article/10.1...
@manuelajoore.bsky.social @sabine-e-grimm.bsky.social
'Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART tool' ➡️ link.springer.com/article/10.1...
@manuelajoore.bsky.social @sabine-e-grimm.bsky.social
Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART tool - PharmacoEconomics
Background Developing health economic decision-analytic models requires making modelling choices to simplify reality while addressing the decision context. Finding the right balance between a decision...
link.springer.com
August 26, 2025 at 4:30 PM
To learn more about SMART, read the paper published on PharmacoEconomics Journal:
'Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART tool' ➡️ link.springer.com/article/10.1...
@manuelajoore.bsky.social @sabine-e-grimm.bsky.social
'Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART tool' ➡️ link.springer.com/article/10.1...
@manuelajoore.bsky.social @sabine-e-grimm.bsky.social
There was a JAMA article looking at pharmacoeconomics/ICER scores in the context of primary prevention where it gotten beaten by Contrave.
Like a lot of drugs, secondary prevention as a primary outcome things look great but primary prevention not so much.
Like a lot of drugs, secondary prevention as a primary outcome things look great but primary prevention not so much.
March 19, 2025 at 3:51 PM
There was a JAMA article looking at pharmacoeconomics/ICER scores in the context of primary prevention where it gotten beaten by Contrave.
Like a lot of drugs, secondary prevention as a primary outcome things look great but primary prevention not so much.
Like a lot of drugs, secondary prevention as a primary outcome things look great but primary prevention not so much.
Pharmacoeconomics (read: pharmacy data monkey)
May 18, 2025 at 11:06 PM
Pharmacoeconomics (read: pharmacy data monkey)
There’s also a branch area of study in pharmacy called pharmacoeconomics. Many pharmacists pursue careers outside the clinical realm in areas such as public health policy and outcomes research and it’s becoming increasingly more common these days.
March 30, 2025 at 5:36 AM
There’s also a branch area of study in pharmacy called pharmacoeconomics. Many pharmacists pursue careers outside the clinical realm in areas such as public health policy and outcomes research and it’s becoming increasingly more common these days.
The agency responsible for evaluating drug treatments in Ireland has said that a "significant price reduction" is expected for weight-loss medicine Mounjaro.
jrnl.ie/7077848
jrnl.ie/7077848
'Significant price reduction' for Mounjaro means the drug may be deemed cost-effective
Manufacturer Eli Lilly has offered a price reduction that may mean the medicine will be deemed cost-effective, according to Michael Barry of the National Centre for Pharmacoeconomics.
jrnl.ie
June 22, 2026 at 9:56 AM
The agency responsible for evaluating drug treatments in Ireland has said that a "significant price reduction" is expected for weight-loss medicine Mounjaro.
jrnl.ie/7077848
jrnl.ie/7077848
New paper out: Cost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology Assessment.: Grand, Tobias Sydendal; Ren, Shijie; Thokala, Praveen; et al.
PharmacoEconomics - open Vol. 10, no. 1, p. 179 - 196 | Thanks for sharing #dzne #papers
PharmacoEconomics - open Vol. 10, no. 1, p. 179 - 196 | Thanks for sharing #dzne #papers
Cost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology Assessment.
Grand, Tobias Sydendal; Ren, Shijie; Thokala, Praveen; et al.
PharmacoEconomics - open Vol. 10, no. 1, p. 179 - 196
dlvr.it
April 18, 2026 at 12:53 PM
𝐏𝐫𝐨𝐣𝐞𝐜𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐏𝐮𝐛𝐥𝐢𝐜 𝐒𝐩𝐞𝐧𝐝𝐢𝐧𝐠 𝐨𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬: 𝐀 𝐑𝐞𝐯𝐢𝐞𝐰 𝐨𝐟 𝐌𝐞𝐭𝐡𝐨𝐝𝐬
Article in PharmacoEconomics: rdcu.be/d5ZTV
Authors: Irina Odnoletkova, Patrice Chalon, Stephan Devriese, Irina Cleemput
The KCE-report (2024): www.kce.fgov.be/en/publicati...
Article in PharmacoEconomics: rdcu.be/d5ZTV
Authors: Irina Odnoletkova, Patrice Chalon, Stephan Devriese, Irina Cleemput
The KCE-report (2024): www.kce.fgov.be/en/publicati...
February 4, 2025 at 9:19 AM
𝐏𝐫𝐨𝐣𝐞𝐜𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐏𝐮𝐛𝐥𝐢𝐜 𝐒𝐩𝐞𝐧𝐝𝐢𝐧𝐠 𝐨𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬: 𝐀 𝐑𝐞𝐯𝐢𝐞𝐰 𝐨𝐟 𝐌𝐞𝐭𝐡𝐨𝐝𝐬
Article in PharmacoEconomics: rdcu.be/d5ZTV
Authors: Irina Odnoletkova, Patrice Chalon, Stephan Devriese, Irina Cleemput
The KCE-report (2024): www.kce.fgov.be/en/publicati...
Article in PharmacoEconomics: rdcu.be/d5ZTV
Authors: Irina Odnoletkova, Patrice Chalon, Stephan Devriese, Irina Cleemput
The KCE-report (2024): www.kce.fgov.be/en/publicati...
In this paper, @rich-norman.bsky.social and I & co-authors examine how to judge when a HRQoL value set becomes 'obsolete'. Some of the value sets used to estimate QALYs are very old. When do they cease to become a valid representation of societal preferences?
tinyurl.com/obsolete-val...
tinyurl.com/obsolete-val...
A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete - PharmacoEconomics
Providing health-related quality of life (HRQoL) value sets to enable estimation of quality adjusted life years (QALYs) is important in facilitating economic evaluation and in supporting reliable deci...
tinyurl.com
February 24, 2025 at 12:50 AM
In this paper, @rich-norman.bsky.social and I & co-authors examine how to judge when a HRQoL value set becomes 'obsolete'. Some of the value sets used to estimate QALYs are very old. When do they cease to become a valid representation of societal preferences?
tinyurl.com/obsolete-val...
tinyurl.com/obsolete-val...
Today the New HTA Regulation comes into force. The comparative evidence for all new medicines for cancer and advanced therapeutic medical products will now be assessed jointly between EU&EEA countries. #EUHTAR @heames.bsky.social www.ncpe.ie/new-european...
New European legislation for Health Technology Assessment welcomed by the NCPE | National Centre for Pharmacoeconomics
www.ncpe.ie
January 12, 2025 at 10:50 AM
Today the New HTA Regulation comes into force. The comparative evidence for all new medicines for cancer and advanced therapeutic medical products will now be assessed jointly between EU&EEA countries. #EUHTAR @heames.bsky.social www.ncpe.ie/new-european...
Reimbursing weight loss drugs for all who could benefit would push State’s annual medicines bill to €10bn, doctors told
Reimbursing weight loss drugs for all who could benefit would push State’s annual medicines bill to €10bn, doctors told
Clinical pharmacoeconomics lead says one million people could benefit from weight loss drugs, but cost would be ‘unaffordable’
www.irishtimes.com
April 26, 2025 at 5:48 AM
Reimbursing weight loss drugs for all who could benefit would push State’s annual medicines bill to €10bn, doctors told
CEVR is thrilled to announce the winners of our 7th Annual Cost-Effectiveness Paper of the Year Award.
Best CEA — Anita Brogan et al. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States (tinyurl.com/mw5ff646)
#CEA #HEOR
Best CEA — Anita Brogan et al. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States (tinyurl.com/mw5ff646)
#CEA #HEOR
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States - PharmacoEconomics
Objective Cabotegravir long-acting (CAB–LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HI...
tinyurl.com
April 9, 2025 at 8:38 PM
CEVR is thrilled to announce the winners of our 7th Annual Cost-Effectiveness Paper of the Year Award.
Best CEA — Anita Brogan et al. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States (tinyurl.com/mw5ff646)
#CEA #HEOR
Best CEA — Anita Brogan et al. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States (tinyurl.com/mw5ff646)
#CEA #HEOR
Can obesity treatment bring both health and environmental benefits? A new paper, co-authored by YHEC's CEO Professor Matthew Taylor, explores the clinical outcomes and carbon footprint of once-weekly semaglutide for people living with obesity in the UK. Read more: link.springer.com/article/10.1...
September 23, 2026 at 10:55 AM
Can obesity treatment bring both health and environmental benefits? A new paper, co-authored by YHEC's CEO Professor Matthew Taylor, explores the clinical outcomes and carbon footprint of once-weekly semaglutide for people living with obesity in the UK. Read more: link.springer.com/article/10.1...
Brought economic theory into cost-effectiveness & decision science 💡 New paper in PharmacoEconomics – Open: When prevention treatments change behavior, they can change their own value — and we need to capture that. Even with riskier behavior, long-acting PrEP stays cost-effective. ✅
Treatment (as Prevention) Availability and Individuals’ Behavior: A Cost-Effectiveness Analysis of Cabotegravir Long-Acting Injectable PrEP - PharmacoEconomics - Open
Background The US Food and Drug Administration (FDA) has approved long-acting injectable agents for preexposure prophylaxis (PrEP) of human immunodeficiency virus (HIV) infection. These agents are urg...
doi.org
August 12, 2025 at 4:03 PM
Brought economic theory into cost-effectiveness & decision science 💡 New paper in PharmacoEconomics – Open: When prevention treatments change behavior, they can change their own value — and we need to capture that. Even with riskier behavior, long-acting PrEP stays cost-effective. ✅